Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
stibium metallicum praeparatum 6x
- Development stage
- Unknown
- Lead developer
- University of Bern
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Stibium metallicum praeparatum 6x (SMP) is an anthroposophic medicinal product being investigated by the University of Bern for the prevention of chemotherapy-induced peripheral neuropathy (CIPN), particularly in early breast cancer patients undergoing paclitaxel treatment. The drug is a homeopathically prepared form of metallic antimony at a 6x decimal dilution. It is administered as a subcutaneous injection three times weekly during chemotherapy and for six weeks following its completion. The clinical efficacy of SMP is being evaluated in the Phase III PROPEL NO TOX trial (NCT04715542), which aims to determine if the treatment can reduce the incidence or severity of neurotoxic symptoms such as pain, numbness, and tingling. While authorized in Switzerland by Swissmedic as an anthroposophic product, its specific molecular mechanism of action remains undefined in conventional pharmacological terms.
- Other names
- stibium metallicumantimony 6xantimony6xantimony-6x
Beyond the preview
Go deeper on stibium metallicum praeparatum 6x.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on stibium metallicum praeparatum 6x.